Company Overview and News

5
AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

2018-09-14 sec.gov
425 Merger of Akebia Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc. Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease September 14, 2018 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Subject Company: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 Date: September 14, 2018
AKBA

5
AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

2018-09-14 sec.gov
425 Merger of Akebia Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc. Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease September 14, 2018 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Subject Company: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 Date: September 14, 2018
AKBA

5
AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

2018-09-06 sec.gov
425 Merger of Akebia Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc. Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease September 6, 2018 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 001-36352 Subject Company: Keryx Biopharmaceuticals, Inc. Commission File No.
AKBA

5
AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

2018-09-06 sec.gov
425 Merger of Akebia Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc. Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease September 6, 2018 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 001-36352 Subject Company: Keryx Biopharmaceuticals, Inc. Commission File No.
AKBA

6
AKBA / Akebia Therapeutics, Inc. / EAGLE ASSET MANAGEMENT INC - null (Passive Investment)

2018-08-31 sec.gov - 1
8/31/18 Securities and Exchange Commission 450 Fifth Street NW Washington, DC 20549 RE: Schedule 13G Akebia Theraputics inc As of 8/31/2018 Gentlemen: In accordance with Section 13(d)(5) of the Securities Exchange Act of 1934, attached please find a copy of Schedule 13G for the above named company showing beneficial ownership change as of 8/31/18 filed on behalf of Eagle Asset Management, Inc. Very truly yours, Damian Sousa Vice President Chief Compliance Officer DS:CC Enclosures cc: Office of the Corporate Secretary Akebia Therapeutics, Inc.
AKBA

6
AKBA / Akebia Therapeutics, Inc. / EAGLE ASSET MANAGEMENT INC - null (Passive Investment)

2018-08-31 sec.gov - 1
8/31/18 Securities and Exchange Commission 450 Fifth Street NW Washington, DC 20549 RE: Schedule 13G Akebia Theraputics inc As of 8/31/2018 Gentlemen: In accordance with Section 13(d)(5) of the Securities Exchange Act of 1934, attached please find a copy of Schedule 13G for the above named company showing beneficial ownership change as of 8/31/18 filed on behalf of Eagle Asset Management, Inc. Very truly yours, Damian Sousa Vice President Chief Compliance Officer DS:CC Enclosures cc: Office of the Corporate Secretary Akebia Therapeutics, Inc.
AKBA

7
AKBA / Akebia Therapeutics, Inc. 8-K (Current Report)

2018-08-28 sec.gov - 2
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AKBA

85
Tracking Seth Klarman's Baupost Group Holdings - Q2 2018 Update

2018-08-14 seekingalpha - 12
The portfolio continues to be heavily concentrated with the top three positions accounting for ~40% of the 13F portfolio.
PCG NSAM.WI CQP PRTK TWX AKBA AR SCACU CAH TRBAB PBF NSAM SLB GE OREX LNG TRBNW VRTV SYF TWC STNL NRF TBPH SCAC SLB MCK OREXQ ATRA SNTL AGN BIIB DIS QRVO GEC NG VSAT ABC CLNY GNE TRCO

5
AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

2018-08-09 sec.gov
425 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 001-36352 Subject Company: Keryx Biopharmaceuticals, I
AKBA

5
AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

2018-08-09 sec.gov
425 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 001-36352 Subject Company: Keryx Biopharmaceuticals, I
AKBA

59
Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag

2018-08-09 zacks - 1
Keryx Biopharmaceuticals, Inc. (KERX - Free Report) incurred a loss of 18 cents per share in the second quarter of 2018, wider than Zacks Consensus Estimate of a loss of 14 cents. The loss was however, narrower than the year-ago loss of 21 cents.
GD GILD ZTO KERX ILMN AKBA

58
Akebia Therapeutics Inc (AKBA) CEO John Butler on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha
Good day, ladies and gentlemen. And welcome to the Akebia Therapeutics Second Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions]. As a reminder, this call is being recorded.
KERX AKBA

5
Avino Silver (ASM) Meets Q2 Earnings Estimates

2018-08-09 zacks
Avino Silver (ASM - Free Report) came out with quarterly earnings of $0.02 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.02 per share a year ago. These figures are adjusted for non-recurring items.
VNOM COLL AKBA

6
Pacific Ethanol (PEIX) Reports Q2 Loss, Misses Revenue Estimates

2018-08-09 zacks
Pacific Ethanol (PEIX - Free Report) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items.
VNOM COLL PEIX AKBA

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 00972D105